期刊在线咨询服务,发表咨询:400-888-9411 订阅咨询:400-888-1571股权代码(211862)

期刊咨询 杂志订阅 购物车(0)

S1-4 Chronic Nicot ine Treatment Alleviates Schizophrenia-Induced Memory Deficit through Regulating Pdlim5 and CRTC1 in Mice

SUN; Yan-yun; WANG; Meng-wei; JIN; Xin-chu Soochow; University; suzhou; 215021; China

关键词:schizophrenia cognitive impairment nicotine pdlim5 

摘要:Objective:Cognitive impairment is a core deficit of schizophrenia and current antipsychotic treatments have no or only very limited effects on cognitive impairment.Clinical studies have found that about 50%~90%of all psychiatric patients are smokers,and the high rate of smoking may be due to the fact that the patients smoke tobacco to reduce their cognitive symptoms.Nicotine is the key psychoactive component and various studies have reported that nicotine can improve cognition under some circumstances.Therefore,we propose our hypothesis that nicotine alleviates schizophreniainduced cognitive impairment.Our published results confirmed that nicotine treatment significantly improved rat’s working memory in the delayed alternate T maze task(DAT).Methods:In this current study,MK-801 was applied to induce schizophrenia-like behavior which was confi rmed by pre-pulse inhibition(PPI)and T-maze used to assess cognitive performance.Results:Our data showed that MK-801 caused cognitive impairment accompanied by an increase of Pdlim5,anadaptor protein that is critically associated with schizophrenia in medial prefrontal cortex(mPFC).Of note,chronic nicotine treatment attenuates MK-801-induced schizophrenia-like symptom as well as cognitive impairment by regulating Pdlim5.In addition,nicotine treatment also reduced MK-801-induced decrease of CREBregulated transcription coactivator 1(CRTC1),a coactivator of CREB which has been shown to play an important role in cognition.More important,MK-801 neither induced schizophrenia-like behavior in pdlim5-/-mice,nor decreased CRTC1 in mPFC.Conclusion:Our results showed that chronic nicotine treatment alleviates schizophrenia-induced memory defi cit through regulating Pdlim5 and CRTC1 in mice.

神经药理学报杂志要求:

{1}包括真实姓名、性别、出生年、职务职称、学位、研究方向、联系电话、E-mail、邮编等。

{2}文稿应论点明确、资料可靠、数据精确、文字精炼、层次清晰。

{3}年份中的前两位数不可省略,如:‘'01年”应为“2001年”。

{4}注释:主要用于对文章篇名、作者及文内某一专题内容作必要的解释或说明。序号在注释处右上角用阿拉伯数字①②等表示。

{5}正文应尽量减少层次,一般不宜超过3层。有标题内容才列数字序号(没有标题的内容用自然段形式起始),数字序号后不用加点,但要空1格。

注:因版权方要求,不能公开全文,如需全文,请咨询杂志社

神经药理学报

省级期刊
1个月内下单

关注 29人评论|0人关注
服务与支付